Literature DB >> 18381941

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?

Ekaterina S Jordanova1, Arko Gorter, Ouissam Ayachi, Frans Prins, Lindy G Durrant, Gemma G Kenter, Sjoerd H van der Burg, Gert Jan Fleuren.   

Abstract

PURPOSE: To investigate the effect of intraepithelial tumor-infiltrating lymphocytes (ieTIL) and their ligands expressed by cervical tumor cells on the outcome of cervical cancer patients. EXPERIMENTAL
DESIGN: The prognostic value of ieTILs was investigated in 115 cases of cervical cancer. T-cell subsets, CD57(+) cells, and regulatory T cells (Treg) were enumerated. The associations of these different ieTIL subtypes with human leukocyte antigen (HLA) class I and MHC class I chain-related molecule A (MICA) expression were determined in relation to clinical variables and patient survival.
RESULTS: Survival analysis showed that a high number of intraepithelial Treg (FoxP3(+)), a low CD8(+)/regulatory T-cell ratio, and a weak HLA-A expression were all associated with worse survival (P=0.034, 0.025, and 0.033, respectively, log-rank test). Further stratification of patient groups based on HLA-A-MICA expression and HLA-A-MICA-CD8(+)/Treg ratio revealed an even poorer survival (P=0.005). In a multivariate Cox analysis, low CD8(+)/Treg ratio (P=0.047), weak HLA-A-MICA expression (P=0.003), and weak HLA-A-MICA expression combined with low CD8(+)/Treg ratio (P=0.002) were all found to be independent unfavorable prognostic predictors in cervical carcinoma (hazard ratios, 2.7, 4.0, and 4.9, respectively).
CONCLUSION: Weak HLA-A-MICA expression combined with low CD8(+)/Treg ratio reveals a patient group with the poorest survival in cervical cancer. As a single variable, low CD8(+)/Treg ratio was a significant independent unfavorable prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381941     DOI: 10.1158/1078-0432.CCR-07-4554

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  87 in total

1.  CD14+ macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: A new therapeutic lead?

Authors:  A Marijne Heeren; Gemma G Kenter; Ekaterina S Jordanova; Tanja D de Gruijl
Journal:  Oncoimmunology       Date:  2015-05-07       Impact factor: 8.110

2.  Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients.

Authors:  Liangliang Wu; Hongyu Liu; Hongchuan Guo; Qiong Wu; Songyan Yu; Yuanyuan Qin; Gang Wang; Qiyan Wu; Rong Zhang; Lingxiong Wang; Lijun Zhang; Chunxi Liu; Shunchang Jiao; Tianyi Liu
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

3.  PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Authors:  Gülçin Gezgin; Sietse J Luk; Jinfeng Cao; Mehmet Dogrusöz; Dirk M van der Steen; Renate S Hagedoorn; Daniëlle Krijgsman; Pieter A van der Velden; Matthew G Field; Gregorius P M Luyten; Karoly Szuhai; J William Harbour; Ekaterina S Jordanova; Mirjam H M Heemskerk; Martine J Jager
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

4.  Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Robert A Redd; Geraldine S Pinkus; Yasodha Natkunam; Azra H Ligon; Courtney F Connelly; Christine J Pak; Christopher D Carey; Sarah E Daadi; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Margaret A Shipp; Scott J Rodig
Journal:  Cancer Immunol Res       Date:  2016-10-13       Impact factor: 11.151

5.  HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.

Authors:  Marloes Gooden; Margit Lampen; Ekaterina S Jordanova; Ninke Leffers; J Baptist Trimbos; Sjoerd H van der Burg; Hans Nijman; Thorbald van Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

Review 6.  Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Authors:  Matthew K Labriola; Kristen A Batich; Jason Zhu; Megan A McNamara; Michael R Harrison; Andrew J Armstrong; Daniel J George; Tian Zhang
Journal:  Clin Genitourin Cancer       Date:  2019-02-05       Impact factor: 2.872

7.  Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples.

Authors:  Simone Punt; Robert J Baatenburg de Jong; Ekaterina S Jordanova
Journal:  J Vis Exp       Date:  2017-07-29       Impact factor: 1.355

Review 8.  Lymphocytes in cancer development: polarization towards pro-tumor immunity.

Authors:  Brian Ruffell; David G DeNardo; Nesrine I Affara; Lisa M Coussens
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-11       Impact factor: 7.638

9.  Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.

Authors:  Reza Nejati; Jennifer B Goldstein; Daniel M Halperin; Hua Wang; Nazila Hejazi; Asif Rashid; Matthew H Katz; Jeffrey E Lee; Jason B Fleming; Jaime Rodriguez-Canales; Jorge Blando; Ignacio I Wistuba; Anirban Maitra; Robert A Wolff; Gauri R Varadhachary; Huamin Wang
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

Review 10.  Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.

Authors:  Sjoerd H van der Burg; Joel M Palefsky
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.